Ifosfamide/mesna plus adriamycin as salvage therapy of advanced epithelial ovarian cancer

Autor: Tangtrakul S, Sarikapan Wilailak, Bullangpoti S, Srisupundit S, Nathpong Israngura, Vasant Linasmita
Rok vydání: 1997
Předmět:
Zdroj: International Journal of Gynecological Cancer. 7:388-391
ISSN: 1525-1438
1048-891X
DOI: 10.1046/j.1525-1438.1997.00020.x
Popis: Linasmita V, Wilailak S, Srisupundit S, Tangtrakul S, Bullangpoti S,Israngura N. Ifosfamide/mesna plus adriamycin as salvage therapy of advancedepithelial ovarian cancer. Int J Gynecol Cancer 1997; 7:388–391. The objective of this study was to determine the efficacy and toxicity ofifosfamide/mesna plus adriamycin as salvage therapy for epithelial ovariancancer (EOC). From October1992 to September 1995, patients with advanced EOC who had their recurrentdisease after platinum and cyclophosphamide received ifosfamide(IFX)/mesna andadriamycin (ADR). IFX wasadministered as a 24-hour infusion at a dose of 1.2 g/m2 daily forthree days and 1.2 g/m2 of mesna were added to the infusion solutionand run for the subsequent 24 hours after completion of the IFX. ADR was given as a singleintravenous bolus at a dose of 50 mg/m2 on day 1. Measurementsinclude objective response,duration of response and toxicities to the therapy regimen. There were 20patients who received the therapy regimen, a total of 54 cycles: their medianage was 50 years, range25–71. Of the 17 evaluable patients, two achieved clinical response (1CR,1PR) for an objective response rate of 11.8%. However, among 14 patientswith platinum-refractorydisease, the response rate was only 7.1% (95% CI 0.2%,33.9%) (1CR, 0PR). At the time of the report, the patient is alivewithout evidence of disease. Eightpatients (47.0%) had stable disease. Median time to progression was fivemonths, range two to six. Alopecia and microscopic hematuria were the commontoxicities. In conclusion,the combination of ifosfamide/mesna and adriamycin has tolerable toxicities,but its efficacy as salvage therapy in platinum-refractory epithelial ovariancancer is modest.
Databáze: OpenAIRE
Externí odkaz: